Statin-induced adverse drug reactions within the conventional dose range may result in fewer collected cases. It has been reported that significant adverse reactions (myopathy) caused by statins are mostly positively related to oral doses. The tendency of simvastatin adverse drug reactions increases with the age of patients, leading to an increased incidence. Therefore, the dosage of these drugs should be strictly controlled to ensure safe use. It is recommended to handle elderly, thin, multi-system disease patients (such as diabetes-induced chronic renal insufficiency), and perioperative patients by enhancing medication monitoring.
Combination drug therapy is an important factor in adverse reactions. In this article, out of 19 cases of ADRs, 18 were combinations. Combination therapy aims to better leverage the synergistic effects of drug treatments and reduce the incidence of adverse reactions. However, failing to pay attention to the types of medications can also lead to a series of ADRs.
The mechanism of action involves more reports on combination therapy adverse reactions [3]. To prevent the occurrence of statin adverse drug reactions, the following drugs should be avoided when used in conjunction: niacin, fibrates and lipid-lowering drugs (Gemfibrozil, Bezafibrate, etc.), macrolide antibiotics (clarithromycin, erythromycin), cyclosporine A, L-thyroxine, mibefradil, nifedipine, diltiazem, nefazodone, antifungal agents, protease inhibitors, and coumarin anticoagulant drugs.
In summary, adverse reactions caused by statin withdrawal and symptomatic treatment have led to most patients improving or being cured, with minimal bodily damage and a serious adverse reaction rate of less than 0.1%. Statins are effective at this stage, with mild adverse reactions, making them effective lipid-lowering drugs. Measures to reduce adverse effects include: (1) appropriate starting dose should not be too large; (2) attention should be paid to medication monitoring during use, with regular testing of liver function and CK, and immediate discontinuation upon discovering adverse reactions; (3) avoid or cautiously combine drugs that can cause rhabdomyolysis and coumarin anticoagulants that inhibit the metabolic pathway of cytochrome P.